XELPROS Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Xelpros, and when can generic versions of Xelpros launch?
Xelpros is a drug marketed by Sun Pharm and is included in one NDA. There are two patents protecting this drug.
This drug has nineteen patent family members in seventeen countries.
The generic ingredient in XELPROS is latanoprost. There are twenty drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the latanoprost profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Xelpros
A generic version of XELPROS was approved as latanoprost by AMRING PHARMS on March 22nd, 2011.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for XELPROS?
- What are the global sales for XELPROS?
- What is Average Wholesale Price for XELPROS?
Summary for XELPROS
International Patents: | 19 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 79 |
Patent Applications: | 6,239 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for XELPROS |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for XELPROS |
What excipients (inactive ingredients) are in XELPROS? | XELPROS excipients list |
DailyMed Link: | XELPROS at DailyMed |
![XELPROS drug patent expirations Drug patent expirations by year for XELPROS](/p/graph/s/t/XELPROS-patent-expirations.png)
![Drug Prices for XELPROS](/p/graph/drug-price/XELPROS.png)
Pharmacology for XELPROS
Drug Class | Prostaglandin Analog |
US Patents and Regulatory Information for XELPROS
XELPROS is protected by two US patents.
Patents protecting XELPROS
Ophthalmic composition comprising a prostaglandin
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REDUCING ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
Ophthalmic composition comprising a prostaglandin
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sun Pharm | XELPROS | latanoprost | EMULSION;OPHTHALMIC | 206185-001 | Sep 12, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Sun Pharm | XELPROS | latanoprost | EMULSION;OPHTHALMIC | 206185-001 | Sep 12, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for XELPROS
See the table below for patents covering XELPROS around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 2197449 | ⤷ Sign Up | |
Mexico | 2010004211 | COMPOSICION OFTALMICA QUE COMPRENDE UNA PROSTAGLANDINA. (OPHTHALMIC COMPOSITION COMPRISING A PROSTAGLANDIN.) | ⤷ Sign Up |
New Zealand | 584555 | STABILISED OPHTHALMIC COMPOSITION COMPRISING A PROSTAGLANDIN AND A POLYETHYLENE GLYCOL HYDROXYSTEARATE SUCH AS SOLUTOL HS 15 | ⤷ Sign Up |
China | 101835473 | ⤷ Sign Up | |
Australia | 2008344909 | ⤷ Sign Up | |
World Intellectual Property Organization (WIPO) | 2009084021 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for XELPROS
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0364417 | 97C0128 | France | ⤷ Sign Up | PRODUCT NAME: LATANOPROST; REGISTRATION NO/DATE IN FRANCE: NL 22549 DU 19970724; REGISTRATION NO/DATE AT EEC: 12716 DU 19960718 |
3461484 | C202130024 | Spain | ⤷ Sign Up | PRODUCT NAME: NETARSUDIL O UN ENANTIOMERO, DIASTEREIOISOMERO, SAL O SALVADO DEL MISMO EN COMBINACION CON LATANOPROST O UNA SAL DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/20/1502; DATE OF AUTHORISATION: 20210107; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1502; DATE OF FIRST AUTHORISATION IN EEA: 20210107 |
3461484 | 301101 | Netherlands | ⤷ Sign Up | PRODUCT NAME: LATANOPROST OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN NETARSUDILMESYLAAT; REGISTRATION NO/DATE: EU/1/20/1502 20210108 |
0364417 | C970039 | Netherlands | ⤷ Sign Up | PRODUCT NAME: [1R-[1 ALPHA (Z),2 BETA(R*),3 ALPHA,5ALPHA]]-7-[3,5-DIHYDROXY-2-(3-HYDROXY-5- FENYLPENTYL)CYCLOPENTYL]-5-HEPTEENZUUR, DESGEWENST IN DE VORM VAN EEN ZOUT OF EEN ESTER, IN HET BIJZONDER LATANOPROSTUM; NAT. REGISTRATION NO/DATE: RVG 21304 19970610; FIRST REGISTRATION: SE 12716 19960718 |
0364417 | 61/1997 | Austria | ⤷ Sign Up | PRODUCT NAME: LATANOPROST UND SEINE THERAPEUTISCH AKTIVEN UND PHYSIOLOGISCH ANNEHMBAREN DERIVATE; NAT. REGISTRATION NO/DATE: 1-22019 19970627; FIRST REGISTRATION: SE 12716 19960718 |
0364417 | SPC/GB97/014 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: LATANOPROST (I.E. 13,14-DIHYDRO-17-PHENYL-18,19,20-TRINOR-PGF-ALPHA-ISOPROPYLESTER); NAT. REGISTRATION NO/DATE: 00032/0220 19961216; FIRST REGISTRATION: SE 12716 19960718; SPC EXTENSION AUTHORISATION: PL00057/1057-008 20101216 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |